A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.

K, Matsueda; S, Harasawa; M, Hongo; N, Hiwatashi; D, Sasaki

doi:10.1080/00365520802240255

Public

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.

Shared by NobleBlocks on Jan 1, 2008 • 12:00 AM UTC

Authors:

Matsueda K

Harasawa S

Hongo M

Abstract

<h4>Objective</h4>Irritable bowel syndrome is characterized by abdominal discomfort and/or pain associated with altered bowel habits. The neurotransmitter serotonin and serotonin type 3 receptors that are extensively distributed on enteric neurons in the human gastrointestinal tract play a role in i...

Discussions